Mesa Laboratories AI Stock Analysis
Want to see MLAB full AI Analyst Report?
Mesa Laboratories (MLAB) AI Stock Analysis
Mesa Laboratories
(NASDAQ:MLAB)
The score is driven primarily by improving financial performance—strong revenue momentum, solid gross margins, strong free cash flow, and better leverage. This is tempered by premium valuation (very high P/E with a low dividend yield) and only mixed technical momentum. Earnings-call guidance supports a steady-to-improving EBITDA trajectory, but operational reliability and segment headwinds (notably clinical genomics) remain notable risks.
Mesa Laboratories Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales by region to show where the company earns its money. For Mesa, geographic splits highlight exposure to key markets, diversification benefits, and risks from local economic or regulatory changes that could affect growth.
US revenue shows steady domestic resilience and remains the backbone of sales, while Other markets have accelerated faster and now rival US contribution—evidence that Mesa is meaningfully diversifying its geographic mix. Conversely China has weakened substantially from prior peaks and is now a shrinking contributor, creating downside risk if that trend continues. Net effect: consolidated growth is being sustained by expansion outside China, but investors should watch management’s plans to solidify gains in Other markets and to reverse or mitigate China headwinds.
The FlyMesa Laboratories (MLAB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $782.43M
- Dividend Yield
- 0.46%
- Average Volume (3M)
- 125.81K
- Price to Earnings (P/E)
- 118.0
- Beta (1Y)
- 1.06
- Revenue Growth
- 2.47%
- EPS Growth
- ―
- Country
- US
- Employees
- 717
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Medical - Specialties
Mesa Laboratories Business Overview & Revenue Model
Company Description
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control seg...
How the Company Makes Money
Mesa Laboratories makes money primarily by selling products and services that support ongoing quality control and compliance workflows, producing a mix of recurring consumables revenue and equipment/service revenue. Key revenue streams include: (1) S...
Mesa Laboratories Earnings Call Summary
The call was predominantly positive, with accelerating organic growth excluding clinical genomics, strong adjusted EBITDA and earnings growth, improved cash generation, debt reduction, lower leverage, and the initiation of fiscal 2027 guidance. The main challenges were the unresolved reliability issue in one sterilization product line, the 8.2% biopharmaceutical development revenue decline, the 8.8% clinical genomics revenue decline and planned revenue reset, margin pressure in Calibration Solutions and clinical genomics, and upcoming restructuring charges. Management characterized the biopharmaceutical development decline as timing- and export-control-related rather than demand-related and described most of the sterilization fix as being in place.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 27, Mesa guides to revenues of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, representing adjusted EBITDA growing about 5% to 8% on revenues up about 0% to 2%, compared with adjusted EBITDA of about $63 million in 2026; the guidance includes the savings plan and its reinvestment and lower clinical genomics revenue, and excludes restructuring charges, which are expected to total pretax charges of $2.6 million to $3.4 million and related cash costs of approximately $2.9 million to 3.7 million. Third quarter revenue is expected to be about flat compared with last year, mainly because clinical genomics revenues stepped down, while outside clinical genomics the businesses are expected to keep growing; Mesa also expects to keep strengthening the balance sheet towards 1.5 to 1.75 turns of net leverage by the end of the fiscal year.
Mesa Laboratories Financial Statement Overview
Summary
Financials are improving with strong TTM revenue growth (64%) and healthy gross margin (~66.6%). Cash generation is a key strength (TTM OCF ~$51.5M, FCF ~$49.5M) and leverage has improved (debt-to-equity ~0.46). Offsetting this, net profitability remains thin (TTM net margin ~2.7%) and results have shown volatility, with modest ROE (~2.6%) and slightly negative TTM FCF growth (-6.47%).
Income Statement
66PositiveBalance Sheet
62PositiveCash Flow
74Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 251.32M | 249.13M | 240.98M | 216.19M | 219.08M | 184.34M |
| Gross Profit | 167.34M | 158.27M | 150.87M | 133.25M | 133.69M | 109.09M |
| EBITDA | 43.60M | 35.28M | 42.35M | -238.38M | 37.52M | 32.53M |
| Net Income | 6.67M | 6.71M | -1.97M | -254.25M | 930.00K | 1.87M |
Balance Sheet | ||||||
| Total Assets | 407.74M | 427.75M | 433.35M | 446.80M | 661.83M | 707.37M |
| Cash, Cash Equivalents and Short-Term Investments | 22.31M | 26.93M | 27.32M | 28.21M | 32.91M | 49.35M |
| Total Debt | 82.25M | 168.83M | 181.47M | 231.30M | 186.14M | 221.13M |
| Total Liabilities | 213.14M | 241.50M | 273.52M | 301.40M | 268.35M | 313.57M |
| Stockholders Equity | 194.60M | 186.25M | 159.83M | 145.39M | 393.48M | 393.80M |
Cash Flow | ||||||
| Free Cash Flow | 49.45M | 39.58M | 42.31M | 41.57M | 23.44M | 34.79M |
| Operating Cash Flow | 51.55M | 42.83M | 46.81M | 44.13M | 27.98M | 39.22M |
| Investing Cash Flow | -2.10M | -3.25M | -4.50M | -81.31M | -9.49M | -305.23M |
| Financing Cash Flow | -48.36M | -41.85M | -44.51M | 32.84M | -33.33M | 52.58M |
Mesa Laboratories Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Positive. The current price of 139.21 is above the 20-day moving average (MA) of 128.10, above the 50-day MA of 128.73, and above the 200-day MA of 105.74, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 61.79 is Neutral, neither overbought nor oversold. The STOCH value of 79.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLAB.
Mesa Laboratories Risk Analysis
Mesa Laboratories disclosed 47 risk factors in its most recent earnings report. Mesa Laboratories reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksMesa Laboratories Peers Comparison
Overall Rating
STE78Outperform- MLAB61Neutral
MASS54Neutral
LAB44Neutral
QDEL37Underperform
TRIB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| STE | 78Outperform | $24.97B | 30.33 | 11.48% | 1.01% | 8.13% | 19.88% |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| MLAB | 61Neutral | $769.51M | 117.97 | 3.52% | 0.46% | 2.47% | ― |
| MASS | 54Neutral | $412.72M | -15.97 | -17.42% | ― | 14.14% | 63.00% |
| LAB | 44Neutral | $262.54M | -5.85 | -7.54% | ― | -34.46% | 47.75% |
| QDEL | 37Underperform | $790.42M | -2.19 | -20.13% | ― | -4.64% | 68.20% |
| TRIB | 37Underperform | $3.79M | -0.13 | 48.72% | ― | -13.28% | 39.65% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MLAB | Mesa Laboratories | 139.21 | 63.84 | 84.70% | |
| LAB | Standard Biotools Inc | 0.64 | -0.56 | -46.42% | |
| QDEL | Quidelortho Corporation | 11.91 | -10.27 | -46.30% | |
| STE | Steris | 256.27 | -1.32 | -0.51% | |
| TRIB | Trinity Biotech | 5.82 | -19.76 | -77.25% | |
| MASS | 908 Devices Inc. | 10.06 | 4.25 | 73.15% |
Mesa Laboratories Corporate Events
Mesa Laboratories Announces Global Restructuring and Cost Savings
NeutralOn October 6, 2026, Mesa Laboratories’ board approved a global restructuring and savings plan aimed at sharpening the focus of its Clinical Genomics division on pharmacogenomics, oncology and high-utilization customer accounts while cutting operating...
Mesa Laboratories Shareholders Back Board And Governance Decisions
PositiveOn September 8, 2026, Mesa Laboratories held its annual meeting of shareholders, with 4,872,692 of 5,595,869 eligible shares represented in person or by proxy. Shareholders elected seven directors, including John Sullivan and Siddhartha Kadia, to one...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026